Publications by authors named "Maria Ferrantini"

Claim this Profile
D
Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.
Luciano Castiello, Paola Sestili, Giovanna Schiavoni, Rosanna Dattilo, Domenica M Monque, Maria Ferrantini

Cancer Immunol Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.
Francesca Spadaro, Caterina Lapenta, Simona Donati, Laura Abalsamo, Vincenzo Barnaba, Maria Ferrantini

Blood· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.
Laura Lattanzi, Carmela Rozera, Diego Marescotti, Giuseppina D'Agostino, Laura Santodonato, Maria Ferrantini

Immunobiology· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68.
Eleonora Aricò, Domenica M Monque, Giuseppina D'Agostino, Federica Moschella, Massimo Venditti, Maria Ferrantini

Vaccine· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.
Stefano M Santini, Caterina Lapenta, Simona Donati, Francesca Spadaro, Filippo Belardelli, Maria Ferrantini

PLoS One· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.
Rosa Conforti, Yuting Ma, Yannis Morel, Carine Paturel, Magali Terme, Maria Ferrantini

Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
Stefano Maria Santini, Caterina Lapenta, Laura Santodonato, Giuseppina D'Agostino, Filippo Belardelli, Maria Ferrantini

Handb Exp Pharmacol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biotherapy of cancer: break the barriers to foster translation of knowledge.
Maria Ferrantini, Claudio Lombardo, Franca Moretti, Filippo Belardelli

Tumori· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2.
Grégoire Mignot, Evelyn Ullrich, Mathieu Bonmort, Cédric Ménard, Lionel Apetoh, Maria Ferrantini

J Immunol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokines, dendritic cells and immunological rejection.
Maria Ferrantini, Filippo Belardelli

Cytokine Growth Factor Rev· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cells and cytokines in immune rejection of cancer.
Maria Ferrantini, Imerio Capone, Filippo Belardelli

Cytokine Growth Factor Rev· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.
Maria Ferrantini, Imerio Capone, Filippo Belardelli

Biochimie· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International meeting "Immunotherapy of cancer: challenges and needs".
Maria Ferrantini, Imerio Capone, Francesco M Marincola, Giorgio Parmiani, Filippo Belardelli

Cancer Immunol Immunother· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Tiziana Di Pucchio, Lorenzo Pilla, Imerio Capone, Maria Ferrantini, Enrica Montefiore

Cancer Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?
Filippo Belardelli, Maria Ferrantini, Giorgio Parmiani, Jeffrey Schlom, Enrico Garaci

Cancer Res· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection.
Eleonora Aricò, Kevin A Robertson, Filippo Belardelli, Maria Ferrantini, Anthony A Nash

Vaccine· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
Nathalie Chaput, Nöel E C Schartz, Fabrice André, Julien Taïeb, Sophie Novault, Maria Ferrantini

J Immunol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Laura Santodonato, Giuseppina D'Agostino, Roberto Nisini, Sabrina Mariotti, Domenica M Monque, Maria Ferrantini

J Immunol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral immune response and protection from viral infection in mice vaccinated with inactivated MHV-68: effects of type I interferon.
Eleonora Aricò, Kevin Robertson, Deborah Allen, Maria Ferrantini, Filippo Belardelli

J Interferon Cytokine Res· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokines as natural adjuvants for vaccines: where are we now?
Paola Rizza, Maria Ferrantini, Imerio Capone, Filippo Belardelli

Trends Immunol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-alpha in tumor immunity and immunotherapy.
Filippo Belardelli, Maria Ferrantini, Enrico Proietti, John M Kirkwood

Cytokine Growth Factor Rev· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokines as a link between innate and adaptive antitumor immunity.
Filippo Belardelli, Maria Ferrantini

Trends Immunol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells.
Elisabetta Padovan, Giulio C Spagnoli, Maria Ferrantini, Michael Heberer

J Leukoc Biol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function.
Paola Matarrese, Luigi Di Biase, Laura Santodonato, Elisabetta Straface, Monica Mecchia, Maria Ferrantini

Am J Pathol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis